Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
And the move will shake up the orthopaedic robotics scene.
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
As assurances that all is well fall on deaf ears, should Glaxosmithkline be thinking more radically?
The repeated failure of Roche’s ipatasertib increases the risk for Astrazeneca’s rival Akt inhibitor capivasertib.